



Press release

SHL announces invitation to a Special General Meeting for approval of grant of 120,000 options to CEO

Tel Aviv / Zurich, 5 November 2020 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN) (“**SHL**” or the “**Company**”), a leading provider and developer of advanced personal telemedicine solutions, today announces that a Special General Meeting (SGM) of the Shareholders of the Company will be held on **December 10, 2020 at 13:00** (Israel Time), at the Company’s registered office, located at 90 Yigal Alon Street, Ashdar Building, Tel Aviv, Israel. The agenda shall include the following matter:

1. Following the approval of the Compensation Committee and of the Board of Directors of the Company (the “**Board**”) – the Approval of Grant of 120,000 Options to Mr. Erez Nachtomy, the Company’s CEO, in accordance with the Company’s Option Plan and Compensation Policy.

All of the above as more fully set forth in the Notice to Shareholders available on the Company’s website.

The record date was set for **November 12, 2020**.

One or more shareholders holding shares representing at least one percent (1%) of the voting rights at the General Meeting may request the Board, in writing, not later than seven (7) days from the date of the invitation to the Special General Meeting, to include an item on the agenda of the Special General Meeting to be held. Such item shall be included on the Special General Meeting’s agenda, provided that the Board found it to be suitable for discussion at the Special General Meeting. Should there be any changes in the agenda of the Special General Meeting due to such shareholder’s request, amended ballot and notice shall be available on the Company’s website at <http://www.shl-telemedicine.com/about-us/investorrelations/general-meeting> not later than fourteen (14) days from the date of the invitation to the Special General Meeting.

The invitation to the SGM shall not be published in newspapers. The full invitation to the SGM can be downloaded on <http://www.shl-telemedicine.com/about-us/investorrelations/general-meeting/>.

For further information please contact:

Martin Meier-Pfister, IRF, Phone: +41 43 244 81 40, shl@irf-reputation.ch

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957). For more information, please visit our web site at www.shl-telemedicine.com.



Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.